Apriem Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.92M | Buy |
13,413
+10
| +0.1% | +$2.22K | 0.28% | 57 |
|
|
2025
Q4 | $3.06M | Sell |
13,403
-85
| -0.6% | -$19.4K | 0.28% | 53 |
|
|
2025
Q3 | $3.12M | Buy |
13,488
+211
| +2% | +$43K | 0.3% | 53 |
|
|
2025
Q2 | $2.46M | Sell |
13,277
-138
| -1% | -$25.6K | 0.26% | 57 |
|
|
2025
Q1 | $2.81M | Buy |
13,415
+100
| +0.8% | +$19.4K | 0.33% | 48 |
|
|
2024
Q4 | $2.37M | Buy |
13,315
+881
| +7% | +$162K | 0.27% | 55 |
|
|
2024
Q3 | $2.46M | Sell |
12,434
-138
| -1% | -$25.8K | 0.29% | 52 |
|
|
2024
Q2 | $2.16M | Sell |
12,572
-107
| -0.8% | -$17.7K | 0.26% | 55 |
|
|
2024
Q1 | $2.31M | Sell |
12,679
-12,797
| -50% | -$2.21M | 0.29% | 52 |
|
|
2023
Q4 | $3.95M | Sell |
25,476
-1,036
| -4% | -$151K | 0.53% | 34 |
|
|
2023
Q3 | $3.95M | Sell |
26,512
-4,829
| -15% | -$709K | 0.58% | 34 |
|
|
2023
Q2 | $4.22M | Buy |
31,341
+6,757
| +27% | +$991K | 0.63% | 33 |
|
|
2023
Q1 | $3.92M | Buy |
24,584
+12,212
| +99% | +$1.87M | 0.63% | 35 |
|
|
2022
Q4 | $2M | Sell |
12,372
-373
| -3% | -$57.2K | 0.35% | 44 |
|
|
2022
Q3 | $1.71M | Sell |
12,745
-828
| -6% | -$119K | 0.31% | 45 |
|
|
2022
Q2 | $2.08M | Sell |
13,573
-563
| -4% | -$86K | 0.36% | 41 |
|
|
2022
Q1 | $2.29M | Sell |
14,136
-895
| -6% | -$130K | 0.34% | 42 |
|
|
2021
Q4 | $2.04M | Buy |
15,031
+37
| +0.2% | +$4.37K | 0.29% | 43 |
|
|
2021
Q3 | $1.62M | Buy |
14,994
+32
| +0.2% | +$3.66K | 0.23% | 47 |
|
|
2021
Q2 | $1.69M | Buy |
14,962
+122
| +0.8% | +$13.7K | 0.25% | 47 |
|
|
2021
Q1 | $1.61M | Sell |
14,840
-50
| -0.3% | -$5.35K | 0.25% | 46 |
|
|
2020
Q4 | $1.6M | Buy |
14,890
+584
| +4% | +$56.1K | 0.28% | 39 |
|
|
2020
Q3 | $1.25M | Buy |
14,306
+364
| +3% | +$34.3K | 0.23% | 47 |
|
|
2020
Q2 | $1.37M | Buy |
13,942
+3,524
| +34% | +$310K | 0.28% | 43 |
|
|
2020
Q1 | $794K | Buy |
10,418
+142
| +1% | +$12.1K | 0.19% | 57 |
|
|
2019
Q4 | $910K | Sell |
10,276
-350
| -3% | -$29.1K | 0.17% | 53 |
|
|
2019
Q3 | $805K | Sell |
10,626
-83,540
| -89% | -$5.73M | 0.18% | 59 |
|
|
2019
Q2 | $6.85M | Buy |
94,166
+6,926
| +8% | +$544K | 2.15% | 18 |
|
|
2019
Q1 | $7.03M | Buy |
87,240
+9,516
| +12% | +$778K | 1.86% | 16 |
|
|
2018
Q4 | $7.17M | Buy |
77,724
+6,851
| +10% | +$602K | 2.52% | 11 |
|
|
2018
Q3 | $6.7M | Buy |
70,873
+185
| +0.3% | +$17.5K | 1.47% | 18 |
|
|
2018
Q2 | $6.55M | Buy |
70,688
+3,450
| +5% | +$337K | 1.47% | 16 |
|
|
2018
Q1 | $6.36M | Sell |
67,238
-4,346
| -6% | -$477K | 1.55% | 18 |
|
|
2017
Q4 | $6.92M | Sell |
71,584
-3,020
| -4% | -$285K | 1.72% | 16 |
|
|
2017
Q3 | $6.63M | Sell |
74,604
-14,357
| -16% | -$1.09M | 1.65% | 15 |
|
|
2017
Q2 | $6.45M | Sell |
88,961
-5,706
| -6% | -$384K | 1.71% | 18 |
|
|
2017
Q1 | $6.17M | Buy |
94,667
+3,980
| +4% | +$250K | 1.68% | 18 |
|
|
2016
Q4 | $5.68M | Buy |
90,687
+1,334
| +1% | +$81.4K | 1.69% | 16 |
|
|
2016
Q3 | $5.63M | Sell |
89,353
-2,021
| -2% | -$131K | 1.68% | 18 |
|
|
2016
Q2 | $5.66M | Buy |
91,374
+1,727
| +2% | +$105K | 1.84% | 15 |
|
|
2016
Q1 | $5.12M | Sell |
89,647
-4,333
| -5% | -$242K | 2.02% | 14 |
|
|
2015
Q4 | $5.57M | Buy |
93,980
+655
| +0.7% | +$37.7K | 1.98% | 10 |
|
|
2015
Q3 | $5.08M | Sell |
93,325
-1,500
| -2% | -$97.6K | 1.88% | 10 |
|
|
2015
Q2 | $6.37M | Sell |
94,825
-875
| -0.9% | -$57.1K | 2.19% | 11 |
|
|
2015
Q1 | $5.6M | Sell |
95,700
-300
| -0.3% | -$18.1K | 1.94% | 16 |
|
|
2014
Q4 | $6.28M | Sell |
96,000
-2,700
| -3% | -$170K | 2.31% | 13 |
|
|
2014
Q3 | $5.7M | Hold |
98,700
| – | – | 2.18% | 10 |
|
|
2014
Q2 | $5.57M | Sell |
98,700
-925
| -0.9% | -$48.5K | 2.13% | 11 |
|
|
2014
Q1 | $5.12M | Sell |
99,625
-825
| -0.8% | -$41.7K | 1.94% | 13 |
|
|
2013
Q4 | $5.3M | Sell |
100,450
-750
| -0.7% | -$36.9K | 2.08% | 12 |
|
|
2013
Q3 | $4.53M | Sell |
101,200
-1,650
| -2% | -$73.1K | 1.96% | 13 |
|
|
2013
Q2 | $4.25M | Buy |
+102,850
| New | +$4.5M | 2.08% | 11 |
|
Other funds holding ABBV
VCM
VPM
Apriem Advisors's ABBV Position: Q1 2026 in Review
Apriem Advisors increased its AbbVie (ABBV) stake by 0.07% in Q1 2026, buying an estimated $2.22K and bringing the position to 13,413 shares worth $2.92M. The position accounts for 0.28% of the portfolio, ranked #57.
Apriem Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.17M in Q4 2018. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Apriem Advisors held 13,413 shares of AbbVie worth $2.92M as of Q1 2026.
- Apriem Advisors bought 10 AbbVie shares in Q1 2026, an estimated $2.22K.
- AbbVie made up 0.28% of Apriem Advisors's portfolio in Q1 2026, its #57 holding.
- Apriem Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Apriem Advisors's AbbVie position peaked at $7.17M in Q4 2018.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Apriem Advisors's 13F filing for Q1 2026, filed 15 May 2026.